Satellos Bioscience (MSLE) Total Non-Current Liabilities (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Total Non-Current Liabilities of -$14.8 million for Q1 2026, down 29.78% quarter-over-quarter from -$11.4 million in Q4 2025.
Satellos Bioscience (MSLE) Total Non-Current Liabilities (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Total Non-Current Liabilities for 2 consecutive years, with -$14.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to -$14.8 million; the TTM figure through Mar 2026 stood at -$14.8 million (changed N/A YoY), while the FY2025 annual figure was -$11.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to -$14.8 million in Q1 2026 per MSLE's latest filing, from -$11.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at -$11.4 million in Q4 2025 and bottomed at -$14.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | -13.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.76 Mn |
| Dec 31, 2025 | -11.38 Mn |